APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Vulvovaginal Candidiasis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Vulvovaginal Candidiasis Treatment Market Outlook and Growth Opportunities 2026

20 December 2025208 pages

Choose your research edition.

Industry ResearchAcute Vulvovaginal Candidiasis Treatment Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Vulvovaginal Candidiasis Treatment Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Acute Vulvovaginal Candidiasis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Vulvovaginal Candidiasis Treatment Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Acute Vulvovaginal Candidiasis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Vulvovaginal Candidiasis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Vulvovaginal Candidiasis Treatment market include Sandoz International GmbH, Novartis AG, Mylan N.V., Pfizer, Inc., Bayer AG., Scynexis, Inc, Phathom Pharmaceutical, Inc, Pacgen Life Science Corporation and NovaDigm Therapeutics, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Acute Vulvovaginal Candidiasis Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Vulvovaginal Candidiasis Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Vulvovaginal Candidiasis Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acute Vulvovaginal Candidiasis Treatment market.

Acute Vulvovaginal Candidiasis Treatment Segment by Company

Sandoz International GmbH

Novartis AG

Mylan N.V.

Pfizer, Inc.

Bayer AG.

Scynexis, Inc

Phathom Pharmaceutical, Inc

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Mycovia Pharmaceuticals, Inc

Lupin

Grupo Ferrer Internacional, S.A

Cidara Therapeutics, Inc

Cadila Pharmaceuticals

Bristol-Myers Squibb Company

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Amplyx Pharmaceuticals Inc

Amneal Pharmaceuticals LLC

Accord Healthcare Ltd

Acute Vulvovaginal Candidiasis Treatment Segment by Type

Nystatin

Ketoconazole

Terconazole

Terbinafine

Clotrimazole

Fluconazole

Others

Acute Vulvovaginal Candidiasis Treatment Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Acute Vulvovaginal Candidiasis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Acute Vulvovaginal Candidiasis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Acute Vulvovaginal Candidiasis Treatment key companies, revenue, market share, and recent developments.

3. To split the Acute Vulvovaginal Candidiasis Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Acute Vulvovaginal Candidiasis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Vulvovaginal Candidiasis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Vulvovaginal Candidiasis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Vulvovaginal Candidiasis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Vulvovaginal Candidiasis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Vulvovaginal Candidiasis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Vulvovaginal Candidiasis Treatment industry.

Chapter 3: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acute Vulvovaginal Candidiasis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acute Vulvovaginal Candidiasis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Vulvovaginal Candidiasis Treatment Industry Trends Table 2. Acute Vulvovaginal Candidiasis Treatment Industry Drivers Table 3. Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges Table 4. Acute Vulvovaginal Candidiasis Treatment Industry Restraints Table 5. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Vulvovaginal Candidiasis Treatment Revenue Share by Company (2021-2026) Table 7. Global Acute Vulvovaginal Candidiasis Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Acute Vulvovaginal Candidiasis Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Acute Vulvovaginal Candidiasis Treatment Company, Product Type & Application Table 10. Global Acute Vulvovaginal Candidiasis Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Acute Vulvovaginal Candidiasis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Nystatin Table 15. Significant Companies of Ketoconazole Table 16. Significant Companies of Terconazole Table 17. Significant Companies of Terbinafine Table 18. Significant Companies of Clotrimazole Table 19. Significant Companies of Fluconazole Table 20. Significant Companies of Others Table 21. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type (2021-2026) Table 25. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Retail Pharmacies Table 27. Significant Companies of Online Pharmacies Table 28. Significant Companies of Hospital Pharmacies Table 29. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application (2021-2026) Table 33. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application (2027-2032) Table 34. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Region (2021-2026) Table 37. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Region (2027-2032) Table 39. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Market Share by Country (2021-2026) Table 42. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Market Share by Country (2027-2032) Table 44. Sandoz International GmbH Company Information Table 45. Sandoz International GmbH Business Overview Table 46. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 48. Sandoz International GmbH Recent Development Table 49. Novartis AG Company Information Table 50. Novartis AG Business Overview Table 51. Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 53. Novartis AG Recent Development Table 54. Mylan N.V. Company Information Table 55. Mylan N.V. Business Overview Table 56. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 58. Mylan N.V. Recent Development Table 59. Pfizer, Inc. Company Information Table 60. Pfizer, Inc. Business Overview Table 61. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 63. Pfizer, Inc. Recent Development Table 64. Bayer AG. Company Information Table 65. Bayer AG. Business Overview Table 66. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 68. Bayer AG. Recent Development Table 69. Scynexis, Inc Company Information Table 70. Scynexis, Inc Business Overview Table 71. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 73. Scynexis, Inc Recent Development Table 74. Phathom Pharmaceutical, Inc Company Information Table 75. Phathom Pharmaceutical, Inc Business Overview Table 76. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 78. Phathom Pharmaceutical, Inc Recent Development Table 79. Pacgen Life Science Corporation Company Information Table 80. Pacgen Life Science Corporation Business Overview Table 81. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 83. Pacgen Life Science Corporation Recent Development Table 84. NovaDigm Therapeutics, Inc Company Information Table 85. NovaDigm Therapeutics, Inc Business Overview Table 86. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 88. NovaDigm Therapeutics, Inc Recent Development Table 89. Mycovia Pharmaceuticals, Inc Company Information Table 90. Mycovia Pharmaceuticals, Inc Business Overview Table 91. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 93. Mycovia Pharmaceuticals, Inc Recent Development Table 94. Lupin Company Information Table 95. Lupin Business Overview Table 96. Lupin Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 98. Lupin Recent Development Table 99. Grupo Ferrer Internacional, S.A Company Information Table 100. Grupo Ferrer Internacional, S.A Business Overview Table 101. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 103. Grupo Ferrer Internacional, S.A Recent Development Table 104. Cidara Therapeutics, Inc Company Information Table 105. Cidara Therapeutics, Inc Business Overview Table 106. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 108. Cidara Therapeutics, Inc Recent Development Table 109. Cadila Pharmaceuticals Company Information Table 110. Cadila Pharmaceuticals Business Overview Table 111. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 113. Cadila Pharmaceuticals Recent Development Table 114. Bristol-Myers Squibb Company Company Information Table 115. Bristol-Myers Squibb Company Business Overview Table 116. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 118. Bristol-Myers Squibb Company Recent Development Table 119. Basilea Pharmaceutica Ltd Company Information Table 120. Basilea Pharmaceutica Ltd Business Overview Table 121. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 123. Basilea Pharmaceutica Ltd Recent Development Table 124. Astellas Pharma Inc Company Information Table 125. Astellas Pharma Inc Business Overview Table 126. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 128. Astellas Pharma Inc Recent Development Table 129. Amplyx Pharmaceuticals Inc Company Information Table 130. Amplyx Pharmaceuticals Inc Business Overview Table 131. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 133. Amplyx Pharmaceuticals Inc Recent Development Table 134. Amneal Pharmaceuticals LLC Company Information Table 135. Amneal Pharmaceuticals LLC Business Overview Table 136. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 138. Amneal Pharmaceuticals LLC Recent Development Table 139. Accord Healthcare Ltd Company Information Table 140. Accord Healthcare Ltd Business Overview Table 141. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 143. Accord Healthcare Ltd Recent Development Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Acute Vulvovaginal Candidiasis Treatment Product Image Figure 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Vulvovaginal Candidiasis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Nystatin Image Figure 8. Ketoconazole Image Figure 9. Terconazole Image Figure 10. Terbinafine Image Figure 11. Clotrimazole Image Figure 12. Fluconazole Image Figure 13. Others Image Figure 14. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type (2021-2032) Figure 17. Retail Pharmacies Image Figure 18. Online Pharmacies Image Figure 19. Hospital Pharmacies Image Figure 20. Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application (2021-2032) Figure 23. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. North America Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. South America Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Nystatin
  • Ketoconazole
  • Terconazole
  • Terbinafine
  • Clotrimazole
  • Fluconazole
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Sandoz International GmbH
  • Novartis AG
  • Mylan N.V.
  • Pfizer, Inc.
  • Bayer AG.
  • Scynexis, Inc
  • Phathom Pharmaceutical, Inc
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc
  • Mycovia Pharmaceuticals, Inc
  • Lupin
  • Grupo Ferrer Internacional, S.A
  • Cidara Therapeutics, Inc
  • Cadila Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Basilea Pharmaceutica Ltd
  • Astellas Pharma Inc
  • Amplyx Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • Accord Healthcare Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Acute Vulvovaginal Candidiasis Treatment Market Dynamics
  1. 2.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
  2. 2.2 Acute Vulvovaginal Candidiasis Treatment Industry Drivers
  3. 2.3 Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges
  4. 2.4 Acute Vulvovaginal Candidiasis Treatment Industry Restraints
3 Acute Vulvovaginal Candidiasis Treatment Market by Company
  1. 3.1 Global Acute Vulvovaginal Candidiasis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Acute Vulvovaginal Candidiasis Treatment Company Ranking (2024-2026)
  4. 3.4 Global Acute Vulvovaginal Candidiasis Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Acute Vulvovaginal Candidiasis Treatment Company Product Type and Application
  6. 3.6 Global Acute Vulvovaginal Candidiasis Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Acute Vulvovaginal Candidiasis Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Acute Vulvovaginal Candidiasis Treatment Market by Type
  1. 4.1 Acute Vulvovaginal Candidiasis Treatment Type Introduction
  2. 4.1.1 Nystatin
  3. 4.1.2 Ketoconazole
  4. 4.1.3 Terconazole
  5. 4.1.4 Terbinafine
  6. 4.1.5 Clotrimazole
  7. 4.1.6 Fluconazole
  8. 4.1.7 Others
  9. 4.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type
  10. 4.2.1 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Type (2021-2032)
  12. 4.2.3 Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type (2021-2032)
5 Acute Vulvovaginal Candidiasis Treatment Market by Application
  1. 5.1 Acute Vulvovaginal Candidiasis Treatment Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application
  6. 5.2.1 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application (2021-2032)
6 Acute Vulvovaginal Candidiasis Treatment Regional Value Analysis
  1. 6.1 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Country, 2025 VS 2032
7 Acute Vulvovaginal Candidiasis Treatment Country-level Value Analysis
  1. 7.1 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Acute Vulvovaginal Candidiasis Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Acute Vulvovaginal Candidiasis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Acute Vulvovaginal Candidiasis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sandoz International GmbH
  2. 8.1.1 Sandoz International GmbH Company Information
  3. 8.1.2 Sandoz International GmbH Business Overview
  4. 8.1.3 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  6. 8.1.5 Sandoz International GmbH Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Mylan N.V.
  14. 8.3.1 Mylan N.V. Company Information
  15. 8.3.2 Mylan N.V. Business Overview
  16. 8.3.3 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  18. 8.3.5 Mylan N.V. Recent Developments
  19. 8.4 Pfizer, Inc.
  20. 8.4.1 Pfizer, Inc. Company Information
  21. 8.4.2 Pfizer, Inc. Business Overview
  22. 8.4.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  24. 8.4.5 Pfizer, Inc. Recent Developments
  25. 8.5 Bayer AG.
  26. 8.5.1 Bayer AG. Company Information
  27. 8.5.2 Bayer AG. Business Overview
  28. 8.5.3 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  30. 8.5.5 Bayer AG. Recent Developments
  31. 8.6 Scynexis, Inc
  32. 8.6.1 Scynexis, Inc Company Information
  33. 8.6.2 Scynexis, Inc Business Overview
  34. 8.6.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  36. 8.6.5 Scynexis, Inc Recent Developments
  37. 8.7 Phathom Pharmaceutical, Inc
  38. 8.7.1 Phathom Pharmaceutical, Inc Company Information
  39. 8.7.2 Phathom Pharmaceutical, Inc Business Overview
  40. 8.7.3 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  42. 8.7.5 Phathom Pharmaceutical, Inc Recent Developments
  43. 8.8 Pacgen Life Science Corporation
  44. 8.8.1 Pacgen Life Science Corporation Company Information
  45. 8.8.2 Pacgen Life Science Corporation Business Overview
  46. 8.8.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  48. 8.8.5 Pacgen Life Science Corporation Recent Developments
  49. 8.9 NovaDigm Therapeutics, Inc
  50. 8.9.1 NovaDigm Therapeutics, Inc Company Information
  51. 8.9.2 NovaDigm Therapeutics, Inc Business Overview
  52. 8.9.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  54. 8.9.5 NovaDigm Therapeutics, Inc Recent Developments
  55. 8.10 Mycovia Pharmaceuticals, Inc
  56. 8.10.1 Mycovia Pharmaceuticals, Inc Company Information
  57. 8.10.2 Mycovia Pharmaceuticals, Inc Business Overview
  58. 8.10.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  60. 8.10.5 Mycovia Pharmaceuticals, Inc Recent Developments
  61. 8.11 Lupin
  62. 8.11.1 Lupin Company Information
  63. 8.11.2 Lupin Business Overview
  64. 8.11.3 Lupin Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  66. 8.11.5 Lupin Recent Developments
  67. 8.12 Grupo Ferrer Internacional, S.A
  68. 8.12.1 Grupo Ferrer Internacional, S.A Company Information
  69. 8.12.2 Grupo Ferrer Internacional, S.A Business Overview
  70. 8.12.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  72. 8.12.5 Grupo Ferrer Internacional, S.A Recent Developments
  73. 8.13 Cidara Therapeutics, Inc
  74. 8.13.1 Cidara Therapeutics, Inc Company Information
  75. 8.13.2 Cidara Therapeutics, Inc Business Overview
  76. 8.13.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  78. 8.13.5 Cidara Therapeutics, Inc Recent Developments
  79. 8.14 Cadila Pharmaceuticals
  80. 8.14.1 Cadila Pharmaceuticals Company Information
  81. 8.14.2 Cadila Pharmaceuticals Business Overview
  82. 8.14.3 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  84. 8.14.5 Cadila Pharmaceuticals Recent Developments
  85. 8.15 Bristol-Myers Squibb Company
  86. 8.15.1 Bristol-Myers Squibb Company Company Information
  87. 8.15.2 Bristol-Myers Squibb Company Business Overview
  88. 8.15.3 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  90. 8.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 8.16 Basilea Pharmaceutica Ltd
  92. 8.16.1 Basilea Pharmaceutica Ltd Company Information
  93. 8.16.2 Basilea Pharmaceutica Ltd Business Overview
  94. 8.16.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  96. 8.16.5 Basilea Pharmaceutica Ltd Recent Developments
  97. 8.17 Astellas Pharma Inc
  98. 8.17.1 Astellas Pharma Inc Company Information
  99. 8.17.2 Astellas Pharma Inc Business Overview
  100. 8.17.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  102. 8.17.5 Astellas Pharma Inc Recent Developments
  103. 8.18 Amplyx Pharmaceuticals Inc
  104. 8.18.1 Amplyx Pharmaceuticals Inc Company Information
  105. 8.18.2 Amplyx Pharmaceuticals Inc Business Overview
  106. 8.18.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  108. 8.18.5 Amplyx Pharmaceuticals Inc Recent Developments
  109. 8.19 Amneal Pharmaceuticals LLC
  110. 8.19.1 Amneal Pharmaceuticals LLC Company Information
  111. 8.19.2 Amneal Pharmaceuticals LLC Business Overview
  112. 8.19.3 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  114. 8.19.5 Amneal Pharmaceuticals LLC Recent Developments
  115. 8.20 Accord Healthcare Ltd
  116. 8.20.1 Accord Healthcare Ltd Company Information
  117. 8.20.2 Accord Healthcare Ltd Business Overview
  118. 8.20.3 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  120. 8.20.5 Accord Healthcare Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst